Jan. 17, 2020:

Pictured from left: Sneha Phadke, DO, University of Iowa, co-investigator of BTCRC-BRE18-337; Oana Danciu, MD, University of Illinois at Chicago, sponsor-investigator of BTCRC-BRE15-016; Kari Wisinski, MD, University of Wisconsin, sponsor-investigator of BTCRC-BRE18-337 and co-investigator of BTCRC-BRE15-016.

Big Ten cancer researchers presented two Big Ten Cancer Research Consortium (Big Ten CRC) studies during the 2019 San Antonio Breast Cancer Symposium in December.

In a poster session, investigators reported on safety results from BTCRC-BRE15-016, a phase 2 study of palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer. Researchers concluded the combination of palbociclib and tamoxifen was well tolerated with expected toxicities, and neutropenia was the most frequently reported adverse event. Researchers noted this is one of the first trials to assess the safety of the combination of palbociclib with tamoxifen in metastatic hormone receptor positive breast cancer and has implications for the early stage setting. See abstract.

Study authors include:

  • Oana C. Danciu, University of Illinois at Chicago, Chicago, IL
  • Kent Hoskins, University of Illinois at Chicago, Chicago, IL
  • Cristina Truica, Penn State Cancer Institute, Hershey, PA
  • Anne Blaes, University of Minnesota, Minneapolis, MN
  • Deimante Tamkus, Michigan State University, Lansing, MI
  • Jatin Rana, Michigan State University, Lansing, MI
  • Pavankumar Tandra, University of Nebraska Medical Center, Omaha, NE
  • Lauren Green, University of Illinois at Chicago, Chicago, IL
  • Li Liu, University of Illinois at Chicago, Chicago, IL
  • Menggang Yu, University of Wisconsin Carbone Cancer Center, Madison, WI
  • Deborah Toppmeyer, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
  • Ruth O’Regan, University of Wisconsin Carbone Cancer Center, Madison, WI
  • Kari Wisinski, University of Wisconsin Carbone Cancer Center, Madison, WI

In an ongoing trials session, researchers reported on BTCRC-BRE18-337, a phase 2 trial with safety run-in of gedatolisib plus talazoparib in advanced triple-negative or BRCA1/2-positive HER2-negative breast cancer. The primary objective of the safety run-in is to determine the recommended phase II dose of talazoparib in combination with gedatolisib in patients with advanced HER2-negative (triple-negative or BRCA1/2-deficient) breast cancer. The primary objective of the phase II study is to estimate the objective response rate (ORR) in patients with BRCA1/2-negative, or unknown, advanced triple-negative breast cancer. See abstract.

Study authors include:

  • Sneha Phadke, University of Iowa, Iowa City, IA
  • Menggang Yu, University of Wisconsin, Madison, WI
  • Kathy Miller, Indiana University, Indianapolis, IN
  • Ami Shah, Northwestern University, Chicago, IL
  • Oana Danciu, University of Illinois, Chicago, IL
  • Kari Wisinski, University of Wisconsin, Madison, WI

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The goal of the Big Ten Cancer Research Consortium is to create a unique team-research culture to drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to almost 9,500 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org.